Work

399P Real-world insights into patients (pts) with advanced NSCLC and MET alterations

Year: 2020

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.10.393

Authors: M. Bittoni, J.C-H. Yang, J-Y. Shih, N. Peled, E. Smit, R. Camidge, D. Carbone, D. Oksen, E. Boutmy, A. Johne, P. Paik

Institutions: The Ohio State University, National Taiwan University Hospital, Soroka Medical Center, The Netherlands Cancer Institute, University of Colorado Anschutz, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Merck KGaA, Yuhan, Daiichi-Sankyo, Ono Pharmaceutical, Genentech, Chugai Pharmaceutical, Daiichi Sankyo Europe

OpenAlex ID: W3107045406

FWCI: 0.282

Cites: 2

Cited by: 2

Related to: 10